Long-term psychological outcomes following stroke: the OX-CHRONIC study

Andrea Kusec[1], Elise Milosevich[1], Owen A. Williams[1], Evangeline G. Chiu[1], Pippa Watson[1], Chloe Carrick[1], Bogna A. Drozdowska[2], Avril Dillon[3], Trevor Jennings[4], Bloo Anderson[4], Helen Dawes[5], Shirley Thomas[6], Annapoorna Kuppuswamy[7,8], Sarah T. Pendlebury[9], Terence J. Quinn[2] and Nele Demeyere[1,9*]

Abstract

Background Stroke survivors rate longer-term (> 2 years) psychological recovery as their top priority, but data on how frequently psychological consequences occur is lacking. Prevalence of cognitive impairment, depression/anxiety, fatigue, apathy and related psychological outcomes, and whether rates are stable in long-term stroke, is unknown.

Methods $N = 105$ long-term stroke survivors (M [SD] age = 72.92 [13.01]; M [SD] acute NIH Stroke Severity Score = 7.39 [6.25]; 59.0% Male; M [SD] years post-stroke = 4.57 [2.12]) were recruited (potential $N = 208$). Participants completed 3 remote assessments, including a comprehensive set of standardized cognitive neuropsychological tests comprising domains of memory, attention, language, and executive function, and questionnaires on emotional distress, fatigue, apathy and other psychological outcomes. Ninety participants were re-assessed one year later. Stability of outcomes was assessed by Cohen's d effect size estimates and percent Minimal Clinically Important Difference changes between time points.

Results On the Montreal Cognitive Assessment 65.3% scored < 26. On the Oxford Cognitive Screen 45.9% had at least one cognitive impairment. Attention (27.1%) and executive function (40%) were most frequently impaired. 23.5% and 22.5% had elevated depression/anxiety respectively. Fatigue (51.4%) and apathy (40.5%) rates remained high, comparable to estimates in the first-year post-stroke. Attention ($d = -0.12$; 85.8% stable) and depression ($d = 0.09$, 77.1% stable) were the most stable outcomes. Following alpha-adjustments, only perceptuomotor abilities ($d = 0.69$; 40.4% decline) and fatigue ($d = -0.33$; 45.3% decline) worsened over one year. Cognitive impairment, depression/anxiety, fatigue and apathy all correlated with worse quality of life.

Conclusion Nearly half of participants > 2 years post-event exhibited psychological difficulties including domains of cognition, mood, and fatigue, which impact long-term quality of life. Stroke is a chronic condition with highly prevalent psychological needs, which require monitoring and intervention development.

Keywords Stroke, Psychological outcomes, Long-term stroke, Cognition, Mood, Fatigue, Apathy

*Correspondence:
Nele Demeyere
nele.demeyere@ndcn.ox.ac.uk
Full list of author information is available at the end of the article

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 2 of 17

Introduction

Globally, stroke is the second highest cause of mortality and is known to increase risk of chronic disability, sustained physical and cognitive impairment, and poorer quality of life that affects both the stroke survivor and carers [1–3]. The typical profile of long-term psychological outcomes post-stroke is not well-characterized, despite the increased likelihood of long-term impairments due to higher survival rates [4, 5]. In a systematic review of unmet care needs of stroke survivors [6], managing psychological outcomes was the most frequently reported unmet need. Psychological information needs, including information on understanding and managing cognition and mood changes post-stroke, were shown to increase from 6 months (22.4%) to 2 years post-stroke (81.4%) [6] due to requiring further information when initial recovery is made or receiving irrelevant information in early stroke.

Psychological outcomes of stroke can include poor attention, memory, executive function, perceptuomotor and language abilities [7], mental health difficulties such as depression and anxiety [8, 9], and extended outcomes such as fatigue and apathy [10, 11]. Difficulties in any of these in early stroke are known to contribute to poorer quality of life, and may reduce daily activity participation [12, 13] and increase need for carer support [4]. However, despite the recognized long-term importance of psychological outcomes [14–16], research has been mainly limited to the first year post-stroke [13, 17, 18].

Longitudinal assessment of cognitive function after stroke has been predominantly completed with brief global screening tools such as the Mini-Mental State Examination (MMSE) [19, 20]. Though choice of tool will depend on the desired cognitive information, post-stroke cognitive impairment often includes deficits in a variety of domains [21], and an in-depth neuropsychological assessment is more feasible outside of the acute window. Mild cognitive impairments are common in chronic stroke [22] and sensitive neuropsychological assessment is therefore warranted in long-term follow-up to detect these often more subtle domain-specific impairments that can still impact quality of life [23]. For example, memory impairments can reduce engagement in daily social tasks (i.e., forgetting positive details of events) and result in increased isolation [24].

Emotional distress after stroke is also common, with post-stroke depression and anxiety estimated to affect 31.0% and 24.2% of stroke survivors respectively [8, 9]. These are frequently accompanied by additional outcomes that can have psychological associations, including fatigue [10], apathy [11] and poor sleep quality [25, 26]. Though evidence suggests these extended outcomes are more common in acute stroke, prevalence rates remain stable at 1-year [27, 28]. Cognitive impairment has been shown to double the risk for emotional distress and extended outcomes in the first-year post-stroke [29–31] and strongly relates to long-term participation in social, community, work, and leisure activities [32]. This emphasizes the need to understand the psychological consequences in a wide variety of areas and considered holistically with regards to their collective impact on post-stroke quality of life.

The temporal nature of these various psychological outcomes in chronic stroke is not well-described. Variability in emotional distress [33] and cognitive functioning (heterogeneous patterns of improvement and decline [34]) has been examined in the first-year post-stroke. However, research in long-term stroke has focused mainly on depression [9], cognitive decline and dementia diagnoses [17]. A more complete and improved understanding of the prevalence and nature of various long-term psychological outcomes is essential to tailoring community stroke services to the needs of stroke survivors.

Study aims and objectives

The OX-CHRONIC study aimed to characterize the psychological profiles of long-term stroke (at least 2 years post-stroke). The primary objective was to identify the long-term prevalence of clinical impairment in six specific cognitive domains (language abilities, number processing, apraxia, memory, spatial attention, and executive function), and extended psychological consequences including depression, anxiety, fatigue, and apathy. Stability of psychological outcomes within a year's time, and the impact of these psychological consequences on quality of life, was also examined. This paper reports on Work Package 4 of the OX-CHRONIC protocol [35] in identifying the longitudinal relationships between post-stroke cognitive impairment to long-term outcomes in quality of life.

Methods

Participants

All participants provided informed consent to take part. The study was approved by the UK National Research Ethics Service committee (REC Reference: 19/SC/0520).

Participants were recruited from the Oxford Cognitive Screening programme, a stroke cohort that had been consecutively recruited from the acute stroke ward within the John Radcliffe Hospital, UK between 2012 and 2020 (see protocol; Demeyere et al [35]). Participants who consented to future studies with the research team following a 6-month post-stroke assessment and who were at least 2 years post-stroke ($N=208$) were contacted for participation in OX-CHRONIC. Participants consenting to OX-CHRONIC completed a battery of self-report and

neuropsychological measures across two time points one year apart (termed Wave 1 and Wave 2), and optionally wore an activity monitor for one week following assessment.[1] With stroke participant consent, their carers were approached about participation, and carers consenting to participation completed self-report questionnaires. Due to the COVID-19 pandemic, all OX-CHRONIC assessments took place remotely either over the telephone or via videoconferencing in up to 3 separate sessions per time point. A detailed description of the full study protocol is reported elsewhere [35].

Patient and public involvement

Stroke survivors were involved in the development of the OX-CHRONIC study and funding application. Two stroke survivors formed part of the study management committee, and one stroke survivor formed part of the study steering committee. The Patient and Public Involvement (PPI) representatives advised how best to adapt study materials when conducted remotely during the pandemic and encouraged data collection via telephone as well as videoconferencing to maximise inclusion. They additionally provided guidance on how and which results to highlight to clinical stroke teams to encourage services to consider the long-term impact of stroke. The PPI representatives collectively contributed to dissemination of OX-CHRONIC results to the general community via public engagement events and news summaries.

Study measures

Neuropsychological assessments selected were based on their wide-range use in stroke settings and covered a wide range of possible cognitive domain impairments. This included domain-general cognition (MoCA [36]), stroke-specific cognition (Oxford Cognitive Screen [OCS] [21]) language (Cookie Theft Task [37]; Boston Naming Test [38]; Letter and Category Fluency [39]), executive function (Trail Making Test A & B [39]; Hayling Sentence Completion Test [40]; OCS-Plus Mixed Trails [41]), memory (Digit Span Forwards & Backwards [42]; Logical Memory Test [42]; Picture Memory Test [41]), attention (Star Cancellation Test [43]), and perceptuomotor abilities (OCS-Plus Figure Copy Test [41]; Rey-Osterrieth Complex Figure Copy Test [44]). To prevent fatigue effects in neuropsychological assessments, study sessions were scheduled across up to 3 separate sessions, and participants were offered breaks within each session.

Validated self-report questionnaires were similarly selected across a range of psychological outcomes (e.g., subjective cognition, emotional distress) and functional information (e.g., activities of daily living). This included previously published measures of cognitive abilities (Cognitive Failures Questionnaire [45]; Cognitive Reserve Index [46]), daily function (Telephone Modified Rankin Scale [47]; Nottingham Extended Activities of Daily Living Scale [48]; 3-item Barthel Index [49]), emotional distress (Hospital Anxiety and Depression Scale [HADS] [50]; Geriatric Depression Scale [GDS] [51]), extended outcomes such as fatigue (Fatigue Severity Scale [FSS] [52]), apathy (Apathy Evaluation Scale [AES] [53]) and sleep quality (Sleep Condition Indicator-8 [SCI-8] [54]), and quality of life measures (EQ-5D-5L [55]; Stroke Impact Scale-Short Form [SF-SIS] [56]; World Health Organization Quality of Life Scale [57]; ICEpop Capability Measure for Adults [58]). Carer measures included the Caregiver Strain Index [59], the Informant-GDS [60], and the Informant Questionnaire for Cognitive Decline in the Elderly (IQ-CODE) [61]. An overview of study measures is in Supplementary Table 1 and in the study protocol [35]. Participants completed self-report measures in their own time to prevent fatigue effects.

Statistical analyses

Analyses were performed using R version 4.2.1 [62]. The datasets analysed and code for the current study are available at osf.io/y2mev.

Descriptive statistics of Wave 1 and Wave 2 study variables were calculated. Where available per measure, validated cut scores (binarized as yes/no) were used to determine percentage of participants with cognitive impairment (for neuropsychological assessments) and scores that indicate elevated symptoms/functional difficulties warranting clinical attention (collectively termed "clinically significant" within the manuscript; for self-report questionnaires only). For study measures, cut scores were developed based on comparison to normative data in healthy adults or based on sensitivity/specificity analyses. Cut scores used in the present study are shown in Supplementary Table 1. Though most measures have been validated both when used remotely and in stroke populations, three self-report cut scores (CFQ [45]; SCI [54]; Informant-GDS [60]) have not yet been validated in stroke, and two neuropsychological assessments (OCS-Plus Trails [41]; Picture Memory Test [42]) have not been validated remotely. 95% confidence intervals for percent estimates were calculated using the below formula:

$$Proportion \pm 1.96 * \frac{\sqrt{Proportion(1 - Proportion)}}{n}$$

To account for potential risk or increased rates of impairment across the large number of more sensitive

---

[1] Activity monitor data will be reported elsewhere.

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 4 of 17

in-depth neuropsychological measures, chi-square tests with false discovery rate corrections were used to determine whether the proportion of those impaired versus not impaired at each time point differed (see Supplementary Materials). Additionally, we do not present data on the proportion of participants with any impairment on the in-depth neuropsychological assessments to further reduce this risk.

To determine stability of psychological outcomes, paired t-tests (for parametric data) and Wilcoxon ranksum tests (for non-parametric data) were used to determine whether a statistically significant change occurred on study measures (instead of proportion of those meeting cut score criteria above) between Wave 1 and Wave 2. Family-wise alpha corrections across neuropsychological assessments and self-report measures were alphaadjusted using false discovery rate (FDR) corrections to balance between risk of Type I and Type II errors. Cohen's *d* was additionally estimated to measure effect size differences. As a comparator, distribution-based Minimal Clinically Important Difference (MCID) estimates (i.e., 0.5 standard deviation change) were used to determine the percentage of participants whose scores were of clinical relevance from Wave 1 to Wave 2. This approach was taken given that some OX-CHRONIC measures do not have published MCIDs in stroke (e.g., Hayling Sentence Completion Test). Where available in the literature per measure, anchor-based MCIDs were additionally used to determine clinically relevant change.

To examine whether potential differences existed at Wave 1 from those retained versus those lost to attrition at Wave 2, independent t-tests were conducted comparing demographics (age, sex, handedness, years of education, stroke type, stroke severity, years poststroke), cognitive impairment (OCS language, memory, attention, number processing, and executive function impairments), and stroke related quality of life scores (SF-SIS stroke recovery score, hand function, arm function, mobility, activities of daily living, emotions, communication, memory and participation). Results are in the Supplementary Materials.

To explore the impact of psychological outcomes on quality of life, Spearman rank correlations, as well as linear regressions controlling for age, sex, years of education, time post-stroke, first versus recurrent stroke, and NIHSS scores, were conducted between cognition (MoCA), depression/anxiety (HADS), fatigue (FSS) and apathy (AES) to EQ-5D-5L health rating scores and SF-SIS scores at Wave 1. Missing data ($n = 19$ missing NIHSS; $n = 7$ missing OCS, MoCA, HADS; $n = 6$ missing EQ-5D-5L; $n = 4$ missing FSS, AES; $n = 3$ missing SF-SIS) was handled using multiple imputation via the *mice* package in R [63]. Imputations were conducted across

five versions with a maximum of 50 iterations via predictive mean matching. Given the most common reason for missingness was information not being available in acute medical records (NIHSS), data was assumed to be Missing at Random.

Results

A total of 105 stroke participants completed OX-CHRONIC Wave 1, with 90 completing re-assessment at Wave 2 one year later. Seventy-four carers participated in Wave 1, and 66 in Wave 2. A recruitment flow chart is shown in Fig. 1 (see study protocol for further details on study sample eligibility [35]).

Participant demographics are presented in Table 1. Our cohort included a high proportion of individuals with left hemisphere stroke (40.00%) and moderate stroke severity scores (median NIHSS = 5).

Participant attrition and study outcomes

Differences in demographics and study measures between those retained ($N = 90$) and those lost to attrition at Wave 2 ($N = 15$) are reported in Supplementary Table 2. Overall, there were no significant differences in demographics or cognition. However, participants lost to attrition self-reported worse overall SF-SIS functioning, lower levels of activities of daily living (ADLs), and worse emotional distress at Wave 1. When comparing those lost to attrition not due to death ($N = 9$) and those retained, there were no statistically significant difference in any variables examined.

Demographics of OX-CHRONIC participants compared to non-participants from the original acute cognitive screening cohort ($N = 761$) did not differ in terms of sex, type of stroke, or acute NIHSS scores. However, individuals not recruited to OX-CHRONIC were on average older at time of stroke, had fewer number of years of education, and were more cognitively impaired (see Supplementary Table 3).

Chronic cognitive impairment

Full details of impairment frequency per neuropsychological measure, per domain, is shown in Table 2. Detailed descriptive statistics (i.e., minimum and maximum scores, task times) are in Supplementary Tables 5 and 6.

At Wave 1, the majority of participants (65.3%) were classified as having a domain-general cognitive impairment on the MoCA (score < 26). When using a strokespecific, multidomain cognitive impairment cutoff score of 22 [64], prevalence of impairment was onethird of the sample at both time points (30.6% Wave 1; 34.1% Wave 2).

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 5 of 17

Fig. 1 Participant recruitment flowchart to OX-CHRONIC at Wave 1 (December 2020 – October 2021) and Wave 2 (December 2021 – October 2022)

At Wave 1, 45.9% ($N=45$) of participants were impaired on at least one of the 10 OCS subtasks (i.e., scored below normative performance of healthy controls [21]). At Wave 2, 47.0% ($N=40$) of participants were impaired in at least one subtask. There was no significant difference between Wave 1 and Wave 2 in presence of any OCS domain impairment ($\chi^2=0.24$, $p=0.88$), and average number of OCS subtasks impaired ($F_{1,181}=0.20$, $p=0.66$).

Across assessment timepoints, attention impairments, particularly in selective visual attention rather than visuospatial neglect, were the most frequently observed using the OCS (Wave 1 21.4% [95% CI 13.3 – 29.6]). When using in-depth neuropsychological measures executive function impairments were most prevalent (Wave 1 30.6% [95% CI 21.5 – 39.7]). Participants were least likely to have expressive language deficits (as low as 1.0% on discourse language on the Cookie Theft task).

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 6 of 17

Table 1 Participant characteristics

Participants (*N* = 105)		Median (IQR)	Min—Max
Sex – *n* (%)			
Male	62 (59.05%)		
Female	43 (40.95%)		
Age – Mean (*SD*)	72.92 (13.01)	74 (14)	21 – 96
Years Post-Stroke – Mean (*SD*)	4.57 (2.12)	4.07 (3.30)	2 – 9.38
Years of Education – Mean (*SD*)	13.94 (3.67)	13 (5)	9 – 23
Stroke Type – *n* (%)			
Ischaemic	86 (81.90%)		
Haemorrhagic	19 (18.10%)		
Lesion Hemisphere – *n* (%)			
Left	42 (40.00%)		
Right	41 (39.05%)		
Bilateral	8 (7.60%)		
Undetermined from scan	14 (13.35%)		
First or Recurrent Stroke – *n* (%)			
First	70 (66.67%)		
Recurrent	35 (33.33%)		
Acute NIHSS Score – Mean (*SD*)	7.39 (6.25)	5 (7)	0 – 27
Carers (*N* = 74)			
Sex – *n* (%)			
Male	27 (36.50%)		
Female	47 (63.50%)		
Relationship to Participant – *n* (%)			
Wife	35 (47.30%)		
Husband	24 (32.40%)		
Daughter/Son	7 (9.40%)		
Parent	5 (6.80%)		
Other	3 (4.10%)		

NIHSS National Institute of Health Stroke Severity

Notably, participants performed well on verbal working memory and verbal episodic recall tasks (e.g., Digit Span Backward, Logical Memory Immediate Recall; impairment rates of 4.1% and 5.1% respectively), while a comparatively high proportion were impaired on the Picture Memory Test (26.5%). In investigating whether proportion of those impaired changed across time points, we find that proportion of impairment stayed stable (see Supplementary Table 7).

Self-reported emotional distress, extended outcomes, and quality of life in chronic stroke

Descriptive statistics of questionnaire data are shown in Table 3. Detailed descriptive statistics (i.e., subscale scores, ranges) are shown in Supplementary Table 8.

Though 30.0% reported at least a moderate disability on the Modified Rankin Scale (score > 3), 55% had a slight disability that affected performance on daily activities (score > 2). Prevalence of self-reported cognitive difficulties were overall lower than that observed using objective neuropsychological measures, with 32.2% reporting clinically significant levels of cognitive failures in everyday life. However, 40% of carers rated their stroke survivor relative at risk of cognitive decline. Prevalence rates for emotional distress varied by measure – 23.5% and 22.5% of stroke survivors reported mild depression and mild anxiety respectively on the HADS, lower than GDS rates (33.4%). Further, 50% of carers rated their relative as having at least mild depression on the informant GDS. Extended outcomes were more frequently endorsed, with clinically significant rates of fatigue observed in 51.5% of participants, and high rates of apathy (40.6%). Significant sleep difficulties were the least frequently reported outcome by stroke survivors (21.0%).

Despite moderate levels of emotional distress and extended outcomes, EQ-5D-5L quality of life scores were comparable to healthy population norms in a similar age bracket [65], and stroke-related quality of life was moderate. Significant carer strain was also low (13.2%).

Time post-stroke did not correlate with any psychological outcomes at Wave 1 following FDR corrections (*r*s = -0.20 – 0.22, *p*s = 0.49 – 0.99; see Supplementary Fig. 1).

Stability of psychological outcomes between wave 1 and wave 2

An overview of whether change in outcomes was statistically and/or clinically meaningful between time points is in Table 4. Detailed information of stability (e.g., comparison to anchor-based MCIDs [66–72]; test statistics) is shown in Supplementary Table 9.

From a statistical perspective, domain-general cognition remained stable between years as measured by number of OCS subtasks impaired (Wilcoxon's $V = 403.50$, $p = 0.39$, Cohen's $d = -0.10$) and MoCA scores ($t = 2.57$, $p = 0.053$, $d = 0.28$). However, when considering anchor-based MCID change, 42.3% of stroke survivors showed decline on the MoCA (vs. 28.2% distribution-based). In an exploratory analysis, visuospatial scores were the only MoCA subtests to decline ($t = 2.52$, $p = 0.01$).

Memory (ds = 0.03 – 0.12) and visuospatial attention tasks ($d = -0.12$) had negligible effect size differences between Wave 1 and Wave 2, though we note 49.4% of participants showed MCID decline on verbal memory on the Digit Span forwards. Discourse language ($d = -1.33$; 83.1% MCID improvement) and executive function tasks ($d = -0.49$, 60.2% MCID improvement) demonstrated moderate to large improvements between years, though complex figure copy abilities showed moderate decline ($d = 0.69$; 40.4% MCID decline).

Kusec *et al. BMC Neurology* (2023) 23:426

Page 7 of 17

Table 2 Descriptive statistics and percent prevalence of impairment status on the stroke-specific Oxford Cognitive Screen subtasks (italicized) and in-depth neuropsychological assessments per domain at Wave 1 (*N* = 98) and Wave 2 (*N* = 85) with 95% confidence intervals. Impairment scores are determined based on comparison to normative data in healthy adults

DOMAIN	WAVE 1 (*N* = 98)		WAVE 2 (*N* = 85)		
	Mean (SD)	Impairment Status *N* (% [95% CI])	Mean (SD)	Impairment Status *N* (% [95% CI])	Cohen's *d*[a]
Domain-General Cognition					
OCS Tasks Impaired	0.90 (1.40)	45 (45.92 [36.1 – 55.8])	0.99 (1.33)	40 (47.06 [36.5 – 57.7])	-0.10
MoCA (< 26)	23.56 (4.16)	64 (65.31 [55.9 – 74.7])	22.98 (4.51)	57 (67.06 [57.1 – 77.1])	0.28
MoCA (< 22)	–	30 (30.61 [21.5 – 39.7])	–	29 (34.12 [24.0 – 44.2])	
Language					
OCS Picture Naming	3.65 (0.59)	4 (4.1 [0.2 – 7.9])	3.71 (0.53)	3 (3.5 [-0.4 – 7.5])	–
OCS Semantics	3 (0)	0 (0.0 [0 – 0])	2.99 (0.11)	1 (1.2 [-1.1 – 3.5])	–
OCS Sentence Reading	14.62 (1.56)	7 (7.1 [2.0– 12.2])	14.59 (1.19)	9 (10.6 [4.0 – 17.1])	–
Cookie Theft Complexity	0.81 (0.23)	1 (1.0 [-0.9 – 3.1])	1.22 (0.24)	1 (1.2 [-1.1 – 3.5])	-1.33
Boston Naming Test	13.89 (1.79)	4 (4.1 [0.2 – 7.9])	–	–	–
Letter Fluency Total	32.53 (14.94)	14 (14.3 [7.4 – 21.2])	32.69 (14.88)	9 (10.7 [4.1 – 17.3])	0.17
Category Fluency Total	31.64 (10.00)	8 (8.2 [2.7 – 13.6])	32.51 (11.09)	7 (8.3 [2.5 – 14.2])	-0.04
Executive Function					
OCS Mixed Trails	10.78 (3.64)	14 (14.3 [7.4 – 21.2])	11.61 (2.17)	4 (4.7 [0.2 – 9.2])	–
Trails A Accuracy	23.81 (0.63)	11 (11.3 [5.1 – 17.6])	23.48 (1.89)	8 (9.4 [3.2 – 15.6])	0.17
Trails B Accuracy	18.54 (6.00)	28 (28.9 [19.9 – 37.8])	18.04 (5.55)	34 (40.0 [29.6 – 50.4])	0.14
Hayling Test Total	12.03 (3.65)	30 (30.6 [21.5 – 39.7])	13.60 (3.93)	20 (23.5 [14.5 – 32.6])	-0.49
OCS-Plus Mixed Trails	10.55 (4.16)	15 (15.5 [8.3 – 22.6])	10.61 (3.76)	23 (27.1 [17.6 – 36.5])	0.01
Memory					
Orientation	3.93 (0.39)	4 (4.1 [0.2 – 7.9])	3.91 (0.40)	5 (5.9 [0.9 – 10.9])	–
Recall	2.57 (1.32)	–	2.74 (1.14)	–	–
Recall + Recognition	3.71 (0.70)	5 (5.1 [0.8 – 9.5])	3.76 (0.55)	3 (3.5 [-0.4 – 7.5])	–
Episodic Recognition	3.84 (0.40)	1 (1.0 [-0.9 – 3.0])	3.79 (0.41)	0 (0.0 [0 – 0])	–
Digit Span Forwards	7.49 (2.33)	9 (9.3 [3.5 – 15.0])	7.25 (2.57)	7 (8.2 [2.4 – 14.1])	0.12
Digit Span Backwards	5.90 (2.14)	4 (4.1 [0.2 – 7.9])	5.89 (2.36)	5 (5.8 [0.8 – 10.9])	0.04
Logical Memory I	12.37 (4.46)	3 (3.1 [-0.3 – 6.5])	12.24 (4.50)	2 (2.4 [-0.8 – 5.6])	0.09
Logical Memory II	10.67 (5.19)	9 (9.3 [3.5 – 15.0])	10.73 (4.96)	6 (7.1 [1.6 – 12.5])	0.03
Picture Memory Test	9.93 (2.73)	26 (26.5 [17.8 – 35.3])	–	–	
Visuospatial Attention					
Broken Hearts Accuracy	43.53 (7.88)	21 (21.4 [13.3 – 29.6])	43.76 (6.57)	23 (27.1 [17.6 – 36.5])	–
Broken Hearts Time	126.73 (38.31)	–	130.33 (37.05)	–	–
Egocentric Neglect	–	8 (8.2 [2.7 – 13.6])	–	7 (8.2 [2.4 – 14.1])	–
Allocentric Neglect	–	8 (8.2 [2.7 – 13.6])	–	7 (8.2 [2.4 – 14.1])	–
Star Cancellation Total	52.19 (5.70)	18 (18.6 [10.9 – 26.3])	52.76 (2.26)	14 (16.5 [8.6 – 24.4])	-0.12
Number Processing					
OCS Number Writing	2.85 (0.41)	12 (12.2 [5.8 – 18.7])	2.79 (0.56)	14 (16.5 [8.6 – 24.4])	–
OCS Calculation	3.77 (0.49)	3 (3.1 [-0.4 – 6.5])	3.69 (0.51)	4 (4.7 [0.2 – 9.2])	–
Perceptuomotor Abilities					
OCS-Plus Figure Copy	54.99 (5.85)	6 (6.1 [1.4 – 10.9])	54.07 (5.19)	5 (5.9 [0.9 – 10.9])	0.17
OCS-Plus Figure Recall	41.46 (10.57)	6 (6.1 [1.4 – 10.9])	39.81 (9.65)	9 (10.6 [4.1 – 17.1])	0.22
ROCF Copy	26.68 (6.38)	10 (10.2 [4.2 – 16.2])	24.04 (6.35)	17 (20.2 [11.7 – 28.8])	0.69
ROCF Recall	12.79 (7.35)	8 (8.3 [2.9 – 13.8])	12.42 (6.61)	4 (9.4 [3.2 – 15.6])	0.17

OCS Oxford Cognitive Screen, *MoCA* Montreal Cognitive Assessment, *WMS* Wechsler Memory Scale, *ROCF* Rey-Osterrieth Complex Figure

[a] Calculated based on repeated measures data (*N* = 85) only

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 8 of 17

Table 3 Descriptive statistics and proportion of sample with clinically elevated scores on self-reported questionnaires for participants and carer-reported measures with 95% confidence intervals. Cut scores used were taken from each scales' published psychometric analysis were used to indicate percent of participants with elevated symptoms or scores warranting clinical attention (termed "clinically significant" within the table)

Domain	N	Mean (SD)	Clinically Significant –N (% [95% CI])
Post-Stroke Abilities			
Modified Rankin Scale Score[a]	100	1.79 (1.27)	30 (28.6 [19.7 – 37.4])
Barthel-3 Item Short Form Total[a]	99	6.93 (1.58)	–
Nottingham Extended ADL[a]	100	47.77 (16.26)	–
Quality of Life			
SIS-Short Form Scaled Total[1a]	102	72.66 (20.12)	–
SIS-Long Form Stroke Recovery Score[b]	88	71.91 (21.63)	–
WHO-QoL–BREF Overall Score[b]	83	7.22 (1.65)	–
ICECAP-A Total[a]	101	15.65 (2.90)	–
EQ5D-5L Health Rating[a]	99	68.61 (18.83)	–
Cognitive Ability			
CFQ Total[b]	88	33.60 (17.93)	29 (32.2 [22.5 – 41.9])
Cognitive Reserve Index[b]	84	128.42 (19.68)	–
Emotional Distress			
HADS-Depression Total[a]	98	4.97 (3.98)	23 (23.5 [15.1 – 31.9])
HADS-Anxiety Total[a]	98	5.23 (4.02)	22 (22.5 [14.2 – 30.7])
GDS Total[a]	101	4.22 (4.10)	34 (33.7 [24.4 – 42.9])
Extended Outcomes			
Apathy Evaluation Scale[a]	101	32.36 (10.21)	41 (40.6 [31.0 – 50.2])
Fatigue Severity Scale[a]	101	35.56 (15.34)	52 (51.5 [41.7 – 61.2])
Sleep Condition Indicator[a]	100	23.29 (8.04)	21 (21.0 [13.0 – 28.9])
Carer Measures			
CSI Total Score[a]	68	2.76 (3.12)	9 (13.2 [5.2 – 21.2])
Informant-GDS Total[a]	70	5.18 (4.30)	35 (50.0 [38.2 – 61.7])
IQ-CODE[a]	74	3.23 (0.63)	29 (39.2 [28.1 – 50.3])

SIS Stroke Impact Scale, *WHO-QoL-BREF* World Health Organization Quality of Life Scale – Abbreviated, *ADL* Activities of Daily Living, *ICECAP-A* ICEpop Capability Measure for Adults, *EQ5D-5L* EuroQol-5 Dimensions-5 Levels, *CFQ* Cognitive Failures Questionnaire, *HADS* Hospital Anxiety and Depression Scale, *GDS* Geriatric Depression Scale, *CSI* Caregiver Strain Index, *IQ-CODE* Informant Questionnaire for Cognitive Decline in the Elderly

[a] Data presented from Wave 1

[b] Data presented from Wave 2

Regarding self-report and carer questionnaires, there were negligible effect size differences across all domains; with emotional distress measures remaining the most stable ($ds = -0.10 – 0.09$; anchor-based MCID no change = 66.0% – 81.8%). However overall perceptions of health (EQ-5D-5L Health Ratings) improved between years ($d = -0.29$, anchor-based MCID improvement = 37.2%), while fatigue worsened over time ($d = -0.33$, anchor-based MCID decline = 45.3%).

Notably, even in this long-term stroke cohort, some measures showed MCID improvement between years – for example, 36.9% had improved executive function abilities and 24.7% had improved depression.

Impact of psychological outcomes on quality of life

Median participant scores were moderate across all SIS domains, though considerable variation was present (see Supplementary Fig. 2). Scaled scores were highest in communication (median = 89.29) and lowest in emotions (median = 72.22).

Correlation scatter plots of cognition, depression, anxiety, fatigue and apathy to long-term OX-CHRONIC quality of life measures is shown in Fig. 2. In regressions controlling for age, sex, years of education, time post-stroke, first vs recurrent stroke, and NIHSS scores, domain-general cognition as measured by the OCS ($B = -1.47$, SE = 1.63, $p = 0.38$) and MoCA ($B = 0.62$, SE = 0.49, $p = 0.21$) did not seem to impact

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 9 of 17

Table 4 Stability results of neuropsychological assessment, self-report, and carer measures per domain between Wave 1 and Wave 2 including Cohen's *d* effect size estimates. Statistical tests were alpha-adjusted using family-wise false discovery rate (FDR) corrections. Distribution-based MCIDs were estimated by calculating percentage of individuals whose difference in scores per measure between Wave 1 and Wave 2 were 0.5 standard deviations (SDs) above or below the mean of each measure at Wave 1. Where available in the literature, anchor-based MCID values were used to represent proportion of those improved, declined or no change between Wave 1 and Wave 2

Domain	Cohen's *d*	MCID	MCID (Anchor or Distribution)		
			Improve	Decline	No Change
Domain-General Cognition					
OCS Tasks Impaired	-0.10	0.69	21.2%	29.4%	49.4%
Montreal Cognitive Assessment	0.28	1.22[a,65]	20.0%	42.3%	37.7%
Language					
Cookie Theft Complexity	**-1.33*****	0.12	**83.1%**	3.6%	13.3%
Letter Fluency Total	0.17	7.46	8.2%	17.6%	74.2%
Category Fluency Total	-0.04	5.00	16.4%	15.3%	68.3%
Executive Function					
Trail Making Test A Accuracy	0.17	0.32	7.1%	15.4%	77.5%
Trail Making Test B Accuracy	0.14	2.99	20.2%	27.3%	52.5%
Hayling A Response Time	**0.46*****	14.52	**32.1%**	4.7%	63.2%
Hayling B Response Time	0.28	23.98	36.9%	8.3%	54.8%
Hayling B Errors	-0.04	5.67	24.1%	28.9%	47.0%
Hayling Test Total	**-0.49*****	0.92	**60.2%**	25.3%	14.5%
OCS-Plus Mixed Accuracy	0.01	2.08	17.8%	21.4%	60.8%
Memory					
Digit Span Forwards	0.12	1.16	3.5%	49.4%	47.1%
Digit Span Backwards	0.04	1.07	18.8%	20.0%	61.2%
Logical Memory Immediate	0.09	2.23	23.5%	30.9%	45.6%
Logical Memory Recall	0.03	2.59	23.8%	29.7%	46.5%
Visuospatial Attention					
Star Cancellation Task Total	-0.12	2.85	9.5%	4.7%	85.8%
Perceptuomotor Abilities					
OCS-Plus Figure Copy	0.17	2.92	12.9%	31.7%	55.4%
OCS-Plus Figure Recall	0.22	5.28	17.6%	31.7%	50.7%
ROCF – Copy	**0.69*****	3.19	3.5%	**40.4%**	56.1%
ROCF – Recall	0.17	3.67	19.2%	22.8%	58.0%
Post-Stroke Abilities					
Modified Rankin Scale Score	-0.23	1[a,66]	16.4%	29.4%	54.2%
Barthel-3 item Total	-0.12	0.79	24.7%	14.1%	61.2%
Quality of Life					
SIS-Short Form Scaled Total	-0.05	10.05	1.1%	1.1%	97.8%
EQ5D-5L Health Rating	**-0.29***	8.61[a,67]	**37.2%**	16.2%	46.6%
Emotional Distress					
HADS-Depression Total	-0.08	2[a,68]	14.1%	14.1%	71.8%
HADS-Anxiety Total	-0.13	2[a,68]	12.9%	21.1%	66.0%
GDS Total	0.09	2[a,69]	16.1%	6.9%	77.1%
Extended Outcomes					
Apathy Evaluation Scale	0.06	5.10	12.7%	14.9%	72.4%
Fatigue Severity Scale	**-0.33***	4.05[a,70]	19.7%	**45.3%**	35.0%
Sleep Condition Indicator	0.07	7.00[a,71]	4.6%	5.8%	89.6%
Carer Measures					
Informant-GDS Total	-0.10	2[a,69]	9.1%	9.1%	81.8%
IQ-CODE	0.34	0.31	15.5%	5.1%	79.4%

MCID Minimal Clinically Important Difference, *OCS* Oxford Cognitive Screen, *ROCF* Rey-Osterrieth Complex Figure Copy, *SIS* Stroke Impact Scale, *EQ5D-5L* EuroQol-5 Dimensions-5 Levels, *HADS* Hospital Anxiety and Depression Scale, *GDS* Geriatric Depression Scale, *IQ-CODE* Informant Questionnaire for Cognitive Decline in the Elderly

[a] Indicates anchor-based MCID value

* *p* < 0.05, ** *p* < 0.01, *** *p* < 0.001 following family-wise FDR corrections

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 10 of 17

Fig. 2 Scatter plots of measures of cognition (OCS, MoCA), depression (HADS-Depression), anxiety (HADS-Anxiety), fatigue (Fatigue Severity Scale) and apathy (Apathy Evaluation Scale) to overall quality of life and stroke-related quality of life using Wave 1 data. EQ-5D-5L: EuroQoL 5D-5L; SF-SIS: Short Form Stroke Impact Scale; OCS: Oxford Cognitive Screen; MoCA: Montreal Cognitive Assessment; HADS: Hospital Anxiety and Depression Scale. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

on overall quality of life as measured by the EQ-5D-5L. However worse cognitive outcomes on the OCS (B=-4.23, SE=1.56, $p < 0.01$) and MoCA (B=-1.73, SE=0.53, $p < 0.01$) correlated with worse stroke-specific quality of life. In contrast, greater fatigue (EQ-5D-5L B=-0.61, SE=0.11, $p < 0.001$; SF-SIS B=-0.72, SE=0.12, $p < 0.001$), depression (EQ-5D-5L B=-2.08, SE=0.43, $p < 0.001$; SF-SIS B=-3.46, SE=0.39, $p < 0.001$), anxiety (EQ-5D-5L B=-2.39, SE=0.43, $p < 0.001$; SF-SIS B=-2.29, SE=0.49, $p < 0.001$), and apathy (EQ-5D-5L B=-0.62, SE=0.19, $p < 0.001$; SF-SIS B=-1.08, SE=0.18, $p < 0.001$) all significantly predicted worse overall and stroke-specific quality of life. Full regression output is in the Supplementary Materials.

Discussion

This study is one of the first in-depth examinations of psychological outcomes in chronic stroke, including addressing long-term cognition, emotional distress, fatigue, and apathy. At an average of 4.5 years post-event, cognitive impairments were present in nearly half of all chronic stroke survivors. Mild to severe levels of depression and anxiety were present in 20%—50% of stroke survivors. Of all outcomes, clinically significant fatigue was the most prevalent, occurring in just over half of participants. Over a one-year period, only perceptuo-motor abilities and fatigue statistically worsened in this chronic sample, while all outcomes showed some clinically meaningful improvement. Lastly, improved psychological outcomes significantly correlated with better perceived quality of life.

Prevalence of domain-general cognitive impairment

Domain-general impairments, as measured by two brief screening tools, ranged from 30% (MoCA < 22 [64]) to 45% (OCS) to 65% (MoCA < 26). Previous research has similarly highlighted wide-ranging estimates of domain-general cognitive impairment. In a London registry study, 22% were estimated to have mild cognitive impairment at 5-years post-stroke on the MMSE [73], whilst other studies report 84% to have mild cognitive impairment at 4 years post-stroke [74] (MoCA < 26). Other MoCA prevalence estimates have ranged from ~79%

at 3 years post-stroke [75], ~46% at 5 years post-stroke [76], to ~61% at 10 years post-stroke [77]. Over a one-year period in the present chronic stroke sample, prevalence rates of domain-general impairments were found to be fairly stable on the OCS (47%) and MoCA (<26; 67%). In meta-analyses of chronic post-stroke cognitive impairment, it would be valuable to assess whether the differences in reported prevalence rates is due to measurement error, stroke-specific vs generic screens, or demographic and clinical factors in the sample. Notably, self-report and carer measures estimated differing rates of cognitive impairment (32% and 39% respectively), demonstrating discrepancies between observed and perceived, subjective cognitive impairments. These are also valuable to consider in prevalence rates of domain-general cognition.

Prevalence of domain-specific cognitive impairment
Domain-specific impairment rates in this cohort are similar to previous cohorts [78–80]. Estimates of domain-specific cognitive impairments varied between OCS brief screening tasks and in-depth neuropsychological assessments. Executive function impairments were the most prevalent using in-depth, sensitive neuropsychological assessments, whereas visuospatial attention impairments were the most prevalent on the OCS (21%), though not notably higher than the in-depth visuospatial assessment (19%). Verbal memory impairments were comparable across brief and in-depth assessments (range 4% – 9%). Visual memory impairments were observed in 27% of participants (higher than previous estimates of ~5% at 2 years post-stroke [80] and ~10% at 7 months post-stroke [81]). Low rates of language impairment were observed in both brief and in-depth assessments (0% – 7%). Language fluency tests had higher rates of impairment (8% – 14%), possibly reflecting the additional executive demands needed for fluency tests. This difference between brief tests and in-depth assessments confirms that unless more sensitive neuropsychological tests are used, these more subtle impairments are likely to be missed in typical post-stroke care. Collectively, findings show executive function abilities, visual memory, and visuospatial attention may be particularly important to monitor in long-term stroke.

Prevalence of emotional distress and extended outcomes
Depression and anxiety rates in this cohort (~25%) are similar to reported estimates in early stroke of up to 12 months (22% anxiety [8]; 31% depression [9]), and in other chronic samples estimating depression at 15 years post-stroke (31% [82]). Notably, depression prevalence was higher when rated by carers (50%), replicating previous research highlighting discrepancies

in early stroke survivor-proxy reports [83] and self-proxy dyads across health conditions more generally [84]. Individuals may feel stigmatized about endorsing depression or be concerned about its impact on family members, and minimize emotional impact of the stroke itself. Thus, carer responses may be more representative. However, carer ratings of participant depression may indicate concern for the stroke survivor, or reflect carer mood [83], thus stroke survivor reports may be more accurate.

Clinically significant fatigue was reported by 51% of participants, consistent with community-based stroke survivors estimates (range 38%—68% [85]), meta-analyses (50% [10]), and early stroke fatigue rates (50% [86]). Our cohort had higher levels of apathy (41%) compared to a systematic review [87] pooled prevalence estimate (35%) and milder stroke cohorts (~36% [88]). Long-term stroke survivors may require improved intervention and support in these areas; however, fatigue and apathy may be more resistant to change relative to depression and anxiety [79]. Sleep difficulties in this cohort (21%) were less prevalent than meta-analytic estimates (38% [89]). Increases in daytime sleepiness are associated with greater time post-stroke, rather than difficulties falling or staying sleep [89] and thus exploring how different sleep difficulties categorizations relate to function would be valuable.

Despite the high frequency of depression, anxiety, apathy, fatigue and sleep disturbances, significant carer strain was relatively low in this cohort (13.2%). Previous work has reported approximately 30% of carers experience significant strain at 6 months post-stroke [90] and 42% at 12 months [91]. Beyond 12 months, carers may become more adept at coping with care responsibilities, or perhaps stroke survivors continue to restore capabilities and require less care. Further research could explore how carer strain changes in relation to care competency and functional capability of the stroke survivor beyond 12 months. Irrespective of carer strain, a systematic review of long-term unmet needs of carers (up to 4 years post-stroke) showed the need for continued psychological information and support to be provided to carers in the long-term after stroke [92].

Stability of psychological outcomes in long term stroke
Domain-general cognitive impairment on the OCS and MoCA were found to be statistically stable. However, when considering MCID change using an anchor-based estimate for the MoCA, 42% of participants declined and 20% improved. Discourse language, executive function and perceptuomotor abilities were statistically most variable across timepoints. The discourse language task was based on visual stimuli, and practice effects [93] are

likely to have contributed to variability. Similarly, executive function measured by the Hayling test improved over one year. However, only response initiation time decreased, suggesting participants improved in response speed only. Like discourse language assessments, it is possible that practice effects with the Hayling Test explains improvements. This may partially explain why 60% demonstrated MCID improvements. It is also possible that speed of response to simple tasks like the Hayling A, which requires individuals to provide a word to complete a common phrase, is easier to improve in long-term stroke, compared to inhibiting automatic responses to common phrases as in the Hayling B where response speed improvements were not observed.

Attention and memory abilities were statistically stable, consistent with previous findings [94, 95]. However, 20%—49% demonstrated decline on memory tasks using MCID metrics. Exploring whether MCID changes in either direction are genuine or simply measurement error requires further research. Although we observed mean shifts in scores, impairment status was found to be stable over time. This could indicate that while improvement can occur in the long-term, individuals may not reach a status of "recovery."

Of all neuropsychological measures, perceptuomotor abilities as measured by the Rey-Osterrieth Complex Figure Copy were found to decline over one year. This was in line with our finding that on the MoCA, only visuospatial scores declined. Importantly, complex figure tasks are highly sensitive and assess multiple cognitive domains including fine motor coordination, planning and organisation, concentration, and visuospatial attention [96, 97], all of which may contribute to the decline observed here. It is possible that its high sensitivity may be capturing individuals who are declining in any of these domains, thus explaining a larger mean response across the cohort. Given the task's inherent complexity, decline may be primarily driven by changes in executive function abilities including working memory. Cerebral small vessel disease, one of the primary causes of stroke [98], is also a hallmark of cognitive decline in vascular dementia. Such decline is also indexed by executive dysfunction (e.g., Prins et al. [99]). In line with this, voxel-based lesion-mapping research in stroke found that poorer overall performance on figure copy tasks was associated with subcortical lesions indicative of small vessel disease [100]. Though none reached a statistically significant threshold, more complex measures of executive function within OX-CHRONIC showed the highest rates of distribution-based MCID decline (e.g., 27.3% Trail Making B accuracy, 28.9% Hayling B Errors). Notably, figure copy tests have high sensitivity [96] with differential functional brain networks associated to performance even

in healthy participants [101]. Of note is our finding that only copy abilities, rather than recalling complex figures, declined, indicating that changes in this task may not extend to short and long-term memory capacity. Given that figure copy tasks likely have less interference from long-term memory domains relative to language based cognitive tasks, the decline observed here may also be primarily due to changes in working memory capacity.

Self- and carer-reported depression and anxiety showed no statistically significant change over time. Emotional outcomes > 2 years post-stroke may therefore be particularly stable. Participants may report higher distress in early stroke regardless of risk for chronic distress. Reviews note declines in depression and anxiety cases in the first year post-stroke [33], however beyond one-year estimates remain stable [9]. Apathy and sleep levels also did not statistically change, aligning with previous work [33, 102]. Similarly, across these measures 50%—77% showed no MCID change. Thus, much like emotional outcomes, apathy and sleep are long-term targets for intervention. Though stroke-related quality of life (98% no MCID change) and functional abilities (54%—61%) were highly consistent between assessment timepoints, there were improvements on the EQ-5D-5L (37% MCID improvement), suggesting that regardless of persistent symptoms, some individuals may experience improvements in the very long-term [103].

The only self-reported outcome to decline over the period of one year was fatigue. Investigating causes of worsening fatigue is a top unmet need reported by both stroke survivors and clinicians [16]. While fatigue levels are not thought to be affected by time post-stroke [89], these data suggest there may be an eventual worsening of fatigue in the very long-term. Whilst replication is warranted, exploring factors relating to fatigue and intervention development is necessary. Likely, there are differing prevalence rates of fatigue subtypes (e.g., physical, emotional, and mental). Establishing the degree to which different subtypes of fatigue impact daily function, and how each subtype relates to outcomes, would be an asset in long-term fatigue management post-stroke.

Clinical implications & future directions
Frequency vs impact on quality of life
Whilst services should anticipate which psychological outcomes are most likely to need clinical attention, adequate time and effort should also go towards supporting those with less prevalent outcomes that may also affect quality of life. For example, though sleep difficulties were one of the least prevalent outcomes here, this does not presume that it has no impact on day-to-day functioning. Similarly, although clinically significant fatigue rates were double that of depression, depression more strongly correlated with

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 13 of 17

stroke-related quality of life. Further, the ways in which quality of life is affected by psychological outcomes is important to understand – greater cognitive impairment was only correlated with stroke-specific quality of life rather than general quality of life, indicating there may be aspects of quality of life that may not be strongly impacted by cognition.

Right treatments at the right time

Findings suggest that the majority of long-term outcomes will remain stable relative to early stroke [34]. However, some stroke survivors demonstrated improvement, contradicting the notion that improvements only occur in the first-year post-stroke. This is further supported by the recent findings of long-term improvement with physical interventions in chronic stroke [104]. This sends a strong positive message that conducting interventions within chronic stroke may be as valuable as interventions in early stroke. Further, we found evidence of significant worsening of fatigue indicating that interventions in chronic stroke may also be valuable to prevent longer-term decline.

Impact of participant attrition

Neither demographic variables, nor nature or severity of cognitive impairment differed between those lost to attrition and those retained. In combination with reasons for attrition (death, poor health, too busy to take part), attrition was likely not due to study-related factors making participation for stroke survivors difficult. However, as individuals lost to attrition self-reported overall poorer SF-SIS functioning, worse ADLs, and greater emotional distress, prevalence in these measures may be less representative. Average NIHSS scores did not differ from stroke survivors recruited acutely, indicating that the OX-CHRONIC cohort has high generalizability. However, stroke survivors lost to attrition were more cognitively impaired at time of acute stroke, which may indicate that cognitive impairment prevalence rates presented here may differ for more severely cognitively impaired individuals.

Remote neuropsychological assessment

Given the breadth of measures used here, it is possible that different measures within domains have different levels of face validity and acceptability to stroke survivors when administered remotely. For example, verbal tasks are easier over the phone, but may be less engaging than completing pen-and-paper tasks. Similarly, verbal tasks may be more susceptible to noise, especially when poor phone or internet connection may be a concern [105, 106]. Comparing psychometric properties and acceptability of different assessments within cognitive domains presents an important area for future research to determine which assessment may be the most useful in remote stroke research.

Limitations

Due to the COVID-19 pandemic, all assessments in OX-CHRONIC were conducted remotely. Though remote administration of the OCS (Tele-OCS) has been validated [107], this format did not allow for apraxia impairments assessment. Though evidence suggests remote assessment of neuropsychological tests are comparable to in-person [108], time-based metrics may be especially more variable via remote assessment. Cut scores for the CFQ, SCI and Informant-GDS have not yet been validated in stroke, nor has the OCS-Plus Trails and Picture Memory Test been validated remotely. Therefore, prevalence estimates in these measures should be interpreted cautiously and may require replication. While time post-stroke did not correlate with key outcomes, OX-CHRONIC comprised a wide range of participants from 2 to 9 years post-acute event. Data collection was completed during the COVID-19 pandemic. Whilst selection and inclusion criteria were not affected, it is possible that individual differences in pandemic experiences affected performance on self-reported quality of life measures and willingness to participate.

Conclusions

Cognitive impairment was present in 45% of chronic stroke survivors. Domain-specific impairments in attention and executive function were the most common in this chronic sample. Memory impairments were the most stable, while discourse language abilities were more variable. There were high rates of depression, anxiety, fatigue, and apathy, and these outcomes correlated with worse quality of life in long-term stroke. This study elucidates the frequency of an array of psychological outcomes in chronic stroke survivors. These findings highlight that psychological consequences of stroke are prevalent and warrant attention in community-based stroke care.

Abbreviations

AES	Apathy Evaluation Scale
CSI	Caregiver Strain Index
HADS	Hospital Anxiety and Depression Scale
ICECAP	ICEpop Capability Measure for Adults
IQ-CODE	Informant Questionnaire on Cognitive Decline in the Elderly
EQ-5D-5L	EuroQol 5-Dimesions 5-Levels
FDR	False Discovery Rate
FSS	Fatigue Severity Scale
GDS	Geriatric Depression Scale
MCID	Minimal Clinically Important Difference
MoCA	Montreal Cognitive Assessment
MMSE	Mini-Mental State Examination
NIHSS	National Institutes of Health Stroke Scale
OCS	Oxford Cognitive Screen
PPI	Patient and Public Involvement
SCI	Sleep Condition Indicator
SF-SIS	Stroke Impact Scale Short Form
WHOQOL-BREF	World Health Organization Quality of Life Brief Version

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 14 of 17

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12883-023-03463-5.

Additional file 1: Supplementary Table 1. Neuropsychological assessments, self-report, and carer measures used in OX-CHRONIC with test metrics and cut off scores used to determine cognitive impairment. Where a range of impairment cutoffs are listed, this is due to some neuropsychological assessments have age-specific cutoffs for cognitive impairment. **Supplementary Table 2.** Mean and frequency statistics of demographic, cognitive, and stroke outcome data for participants that were retained across time points ($N = 90$) and those who withdrew ($N = 15$). **Supplementary Table 3.** Mean and frequency statistics of demographic and cognitive data for participants that were retained up until the OX-Chronic study ($N = 105$) and those who withdrew at any time point following acute assessment ($N = 761$). **Supplementary Figure 1.** Pearson correlations of time post-stroke (in years) to all study outcome variables using Wave 1 data ($N = 105$). Following false discovery rate corrections, no variable was significantly correlated with time post-stroke. Variables are shown on the x-axis, with values arranged in ascending order from left to right. Correlation values ranged from -0.20 (Digi Span Forward) to 0.22 (Rey-Osterrieth Complex Figure-Recall). **Supplementary Table 4.** Controlled regression output investigating the role of psychological outcomes to stroke-specific (SF-SIS) and general quality of life (EQ-5D-5L) using Wave 1 OX-CHRONIC data ($N = 105$). Missing data was accounted for using multiple imputation via predictive mean matching. **Supplementary Table 5.** Descriptive and impairment prevalence statistics per domain on the Oxford Cognitive Screen (OCS) at Wave 1 ($N = 98$) and Wave 2 ($N = 85$). Impairment scores were calculated using normative data published in Demeyere et al. (2015). **Supplementary Table 6.** Descriptive and impairment prevalence statistics per domain using in-depth neuropsychological assessments at Wave 1 ($N = 98$) and Wave 2 ($N = 85$). Impairment scores used are shown in Supplementary Table 1. **Supplementary Table 7.** Chi-square evaluations of whether proportion of individuals impaired differs across time points. False discovery rate adjustments on p-values from chi-square tests. **Supplementary Table 8.** Descriptive statistics on self-reported and carer questionnaire measures. Clinical cutoff scores are in Supplementary Table 1. WHO = World Health Organization; ADL = Activities of Daily Living; ICECAP-A = ICEpop Capability Measure for Adults; EQ5D-5L = EuroQol-5 Dimensions-5 Levels. **Supplementary Table 9.** Complete case test statistics of neuropsychological assessment, self-report, and carer measures per domain between Wave 1 and Wave 2 ($N = 90$) including standardized mean difference scores and Cohen's *d* effect size estimates. Statistical tests were alpha-adjusted using false discovery rate (FDR) corrections. Distribution-based MCIDs were estimated by calculating percentage of individuals whose difference in scores per measure between Wave 1 and Wave 2 were 0.5 standard deviations (SDs) above or below the mean of each measure at Wave 1. Where available, published anchor-based MCID estimates were used to compare to distribution-based MCIDs (referenced by number). **Supplementary Figure 2.** Distributions of Stroke Impact Scale subscales in chronic stroke using complete cases at Wave 2 ($N = 90$). Median points with quantile ranges are shown within boxplots. Higher scaled scores represent better functioning. Scaled scores were highest in the domain of communication (median = 89.29), followed by hand function (median = 85), memory (median = 84.52), activities of daily living (median = 82.50), mobility (median = 80.56), arm function (median = 75), and participation (median = 73.44), with emotions having the lowest self-reported scores (median = 72.22).(DOCX 630 KB)

Availability of data and materials

The dataset supporting the conclusions of this article is available in the study-specific Open Science Framework repository: osf.io/y2mev.

Declarations

Ethics approval and consent to participate

This study received ethical approval from the Health Research Authority—South Central Berkshire Research Ethics Committee approved this study (REC Reference: 19/SC/0520). All methods were conducted in accordance with the Declaration of Helsinki. All participants provided informed consent to participate in the study.

Consent for publication

Not applicable.

Competing interests

ND is a developer of the Oxford Cognitive Screen but does not receive any remuneration from its use. TJQ chairs the DMC for a vascular cognitive impairment trial supported by NovoNordisk; TJQ has provided outcomes assessment and advisory board input for trials in cognition for Novartis, NovoNordisk. All other authors declare no competing interests.

Author details

[1]Department of Experimental Psychology, University of Oxford, Anna Watts Building, Radcliffe Observatory Quarter, Oxford, UK. [2]School of Cardiovascular & Metabolic Health, University of Glasgow, Glasgow, UK. [3]Department of Health and Life Sciences, Oxford Brookes University, Oxford, UK. [4]Patient and Public Involvement Representative, Oxford, UK. [5]NIHR Exeter Biomedical Research Centre, University of Exeter, Medical School Building, St Luke's Campus, Magdalen Road, Exeter, UK. [6]School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham, UK. [7]Institute of Neurology Department of Clinical and Movement Neurosciences, University College London, 33 Queen Square, London, UK. [8]Department of Biomedical Sciences, University of Leeds, Leeds, UK. [9]Wolfson Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.

References

1. Van De Port IGL, Kwakkel G, Van Wijk I, et al. Susceptibility to deterioration of mobility long-term after stroke: a prospective cohort study. Stroke. 2006;37(1):167–71.
2. Jaillard A, Naegele B, Trabucco-Miguel S, et al. Hidden dysfunctioning in subacute stroke. Stroke. 2009;40(7):2473–9.
3. Nys GM, Van Zandvoort MJ, De Kort PL, et al. Cognitive disorders in acute stroke: prevalence and clinical determinants. Cerebrovasc Dis. 2007;23(5–6):408–16.

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 15 of 17

4.   Seminog OO, Scarborough P, Wright FL, Rayner M, Goldacre MJ. Determinants of the decline in mortality from acute stroke in England: linked national database study of 795 869 adults. BMJ. 2019;22:365.

5.   Johnson CO, Nguyen M, Roth GA, Nichols E, Alam T, Abate D, Abd-Allah F, Abdelalim A, Abraha HN, Abu-Rmeileh NM, Adebayo OM. Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439–58.

6.   Lin BL, Mei YX, Wang WN, Wang SS, Li YS, Xu MY, Zhang ZX, Tong Y. Unmet care needs of community-dwelling stroke survivors: a systematic review of quantitative studies. BMJ Open. 2021;11(4):e045560.

7.   Lo JW, Crawford JD, Desmond DW, Godefroy O, Jokinen H, Mahinrad S, Bae HJ, Lim JS, Köhler S, Douven E, Staals J. Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. Neurology. 2019;93(24):e2257–71.

8.   Knapp P, Dunn-Roberts A, Sahib N, Cook L, Astin F, Kontou E, Thomas SA. Frequency of anxiety after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2020;15(3):244–55. https://doi.org/10.1177/1747493019896958.

9.   Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014;9(8):1017–25. https://doi.org/10.1111/ijs.12357.

10.   Cumming TB, Packer M, Kramer SF, English C. The prevalence of fatigue after stroke: a systematic review and meta-analysis. Int J Stroke. 2016;11(9):968–77. https://doi.org/10.1177/1747493016669861.

11.   Tay J, Morris RG, Markus HS. Apathy after stroke: diagnosis, mechanisms, consequences, and treatment. Int J Stroke. 2021;16(5):510–8.

12.   Mole JA, Demeyere N. The relationship between early post-stroke cognition and longer term activities and participation: a systematic review. Neuropsychol Rehabil. 2020;30(2):346–70.

13.   Stolwyk RJ, Mihaljcic T, Wong DK, Chapman JE, Rogers JM. Poststroke cognitive impairment negatively impacts activity and participation outcomes: a systematic review and meta-analysis. Stroke. 2021;52(2):748–60. https://doi.org/10.1161/STROKEAHA.120.032215.

14.   Andrew NE, Kilkenny M, Naylor R, Purvis T, Lalor E, Moloczij N, Cadilhac DA, National Stroke Foundation. Understanding long-term unmet needs in A ustralian survivors of stroke. Int J Stroke. 2014;9:106–12.

15.   Abrahamson V, Wilson PM. How unmet are unmet needs post-stroke? A policy analysis of the six-month review. BMC Health Serv Res. 2019;19:1–9.

16.   Hill G, Regan S, Francis R, Mead G, Thomas S, Salman RA, Roffe C, Pollock A, Davenport S, Kontou E, Chadd K. Research priorities to improve stroke outcomes. Lancet Neurol. 2022;21(4):312–3. https://doi.org/10.1016/S1474-4422(22)00044-8.

17.   Lo JW, Crawford JD, Desmond DW, Bae HJ, Lim JS, Godefroy O, Roussel M, Kang Y, Jahng S, Köhler S, Staals J. Long-term cognitive decline after stroke: an individual participant data meta-analysis. Stroke. 2022;53(4):1318–27. https://doi.org/10.1161/STROKEAHA.121.035796.

18.   Sexton E, McLoughlin A, Williams DJ, Merriman NA, Donnelly N, Rohde D, Hickey A, Wren MA, Bennett K. Systematic review and meta-analysis of the prevalence of cognitive impairment no dementia in the first year post-stroke. Eur Stroke J. 2019;4(2):160–71. https://doi.org/10.1177/2396987318825484.

19.   Tang EY, Amiesimaka O, Harrison SL, Green E, Price C, Robinson L, Siervo M, Stephan BC. Longitudinal effect of stroke on cognition: a systematic review. J Am Heart Assoc. 2018;7(2):e006443.

20.   Saa JP, Tse T, Baum C, Cumming T, Josman N, Rose M, Carey L. Longitudinal evaluation of cognition after stroke - A systematic scoping review. PLoS One. 2019;14(8):e0221735. https://doi.org/10.1371/journal.pone.0221735.

21.   Demeyere N, Riddoch MJ, Slavkova ED, Bickerton WL, Humphreys GW. The Oxford Cognitive Screen (OCS): validation of a stroke-specific short cognitive screening tool. Psychol Assess. 2015;27(3):883.

22.   Rebchuk AD, Kuzmuk LE, Deptuck HM, Silverberg ND, Field TS. Evaluating high-functioning young stroke survivors with cognitive complaints. Can J Neurol Sci. 2022;49(3):368–72. https://doi.org/10.1017/cjn.2021.137.

23.   Lee PH, Yeh TT, Yen HY, Hsu WL, Chiu VJ, Lee SC. Impacts of stroke and cognitive impairment on activities of daily living in the Taiwan longitudinal study on aging. Sci Rep. 2021;11(1):1–9. https://doi.org/10.1038/s41598-021-91838-4.

24.   Elayoubi J, Nelson ME, Haley WE, Hueluer G. The role of social connection/engagement in episodic memory change in stroke. Gerontologist. 2022;62(3):364–74. https://doi.org/10.1093/geront/gnab095.

25.   Baylan S, Griffiths S, Grant N, Broomfield NM, Evans JJ, Gardani M. Incidence and prevalence of post-stroke insomnia: a systematic review and meta-analysis. Sleep Med Rev. 2020;1(49):101222.

26.   Fulk GD, Boyne P, Hauger M, Ghosh R, Romano S, Thomas J, Slutzky A, Klingman K. The impact of sleep disorders on functional recovery and participation following stroke: a systematic review and meta-analysis. Neurorehabil Neural Repair. 2020;34(11):1050–61.

27.   Caeiro L, Ferro JM, eMelo TP, Canhão P, Figueira ML. Post-stroke apathy: an exploratory longitudinal study. Cerebrovascular Dis. 2013;35(6):507–13.

28.   Alghamdi I, Ariti C, Williams A, Wood E, Hewitt J. Prevalence of fatigue after stroke: a systematic review and meta-analysis. Eur Stroke J. 2021;6(4):319–32. https://doi.org/10.1177/23969873211047681.

29.   Williams OA, Demeyere N. Association of depression and anxiety with cognitive impairment 6 months after stroke. Neurology. 2021;96(15):e1966–74.

30.   Falck RS, Best JR, Davis JC, Eng JJ, Middleton LE, Hall PA, Liu-Ambrose T. Sleep and cognitive function in chronic stroke: a comparative cross-sectional study. Sleep. 2019;42(5):zsz040. https://doi.org/10.1093/sleep/zsz040.

31.   Skogestad IJ, Kirkevold M, Larsson P, Borge CR, Indredavik B, Gay CL, Lerdal A. Post-stroke fatigue: an exploratory study with patients and health professionals to develop a patient-reported outcome measure. J Patient-Reported Outcomes. 2021;5(1):1–1.

32.   Ezekiel L, Collett J, Mayo NE, Pang L, Field L, Dawes H. Factors associated with participation in life situations for adults with stroke: a systematic review. Arch Phys Med Rehabil. 2019;100(5):945–55.

33.   Carnes-Vendrell A, Deus J, Molina-Seguin J, Pifarré J, Purroy F. Depression and apathy after transient ischemic attack or minor stroke: prevalence, evolution and predictors. Sci Rep. 2019;9(1):16248.

34.   Demeyere N, Sun S, Milosevich E, Vancleef K. Post-stroke cognition with the Oxford Cognitive Screen vs Montreal Cognitive Assessment: a multi-site randomized controlled study (OCS-CARE). AMRC Open Res. 2019;13(1):12.

35.   Demeyere N, Williams OA, Milosevich E, et al. Long-term psychological consequences of stroke (OX-CHRONIC): a longitudinal study of cognition in relation to mood and fatigue after stroke: protocol. Eur Stroke J. 2021;6(4):428–37. https://doi.org/10.1177/23969873211046120.

36.   Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–9.

37.   Kaplan E. The Assessment of Aphasia and Related Disorders. Philadelphia: Lippincott Williams & Wilkins; 1983.

38.   Mack WJ, Freed DM, Williams BW, et al. Boston naming test: shortened versions for use in Alzheimer's disease. J Gerontol. 1992;47(3):P154–8.

39.   Delis DC, Kaplan E, Kramer JH. Delis-Kaplan executive function system. San Antonio (USA): Pearson; 2001.

40.   Burgess P, Shallice T. The Hayling and Brixton tests. Bury St Edmunds (GB):Thames Valley Company; 1997.

41.   Demeyere N, Haupt M, Webb SS, et al. Introducing the tablet-based Oxford Cognitive Screen-Plus (OCS-Plus) as an assessment tool for subtle cognitive impairments. Sci Rep. 2021;11(1):8000.

42.   Wechsler D, Edition WM. Wechsler Memory Scale-III. San Antonio (USA): Pearson; 1997.

43.   Wilson B, Cockburn J, Halligan PW. Behavioural inattention test thames valley test company: Titchfield. Hampshire. 1987.

44.   Osterrieth PA. Le test de copie d'une figure complexe; contribution a l'etude de la perception et de la memoire. Arch de psychologie. 1944;30:206–356.

45.   Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The cognitive failures questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21(1):1–6.

46.   Nucci M, Mapelli D, Mondini S. Cognitive Reserve Index questionnaire (CRIq): a new instrument for measuring cognitive reserve. Aging Clin Exp Res. 2012;24:218–26.

47.   Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604–7.

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 16 of 17

48. Nouri FM, Lincoln NB. An extended activities of daily living scale for stroke patients. Clin Rehabil. 1987;1(4):301–5.

49. Ellul J, Watkins C, BArer D. Estimating total Barthel scores from just three items: the European Stroke Database 'minimum dataset'for assessing functional status at discharge from hospital. Age Ageing. 1998;27(2):115–22.

50. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361–70.

51. Yesavage JA. Geriatric depression scale. Psychopharmacol Bull. 1988;24(4):709–11.

52. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.

53. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res. 1991;38(2):143–62.

54. Espie CA, Kyle SD, Hames P, et al. The sleep condition indicator: a clinical screening tool to evaluate insomnia disorder. BMJ Open. 2014;4(3):e004183.

55. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.

56. Jenkinson C, Fitzpatrick R, Crocker H, Peters M. The Stroke Impact Scale: validation in a UK setting and development of a SIS short form and SIS index. Stroke. 2013;44(9):2532–5.

57. Whoqol Group. Development of the World Health Organization WHO-QOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551–8.

58. Al-Janabi HN, Flynn T, Coast J. Development of a self-report measure of capability wellbeing for adults: the ICECAP-A. Qual Life Res. 2012;21:167–76.

59. Robinson BC. Validation of a caregiver strain index. J Gerontol. 1983;38(3):344–8.

60. Brown LM, Schinka JA. Development and initial validation of a 15-item informant version of the geriatric depression scale. Int J Geriatr Psychiatry. 2005;20(10):911–8.

61. Jorm AF, Jacomb PA. The informant questionnaire on cognitive decline in the elderly (IQCODE): sociodemographic correlates, reliability, validity and some norms. Psychol Med. 1989;19(4):1015–22.

62. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, 2021. Available from:https://www.R-project.org/.

63. Van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;12(45):1–67.

64. Shi D, Chen X, Li Z. Diagnostic test accuracy of the Montreal Cognitive Assessment in the detection of post-stroke cognitive impairment under different stages and cutoffs: a systematic review and meta-analysis. Neurol Sci. 2018;39:705–16.

65. Janssen MF, Pickard AS, Shaw JW. General population normative data for the EQ-5D-3L in the five largest European economies. Eur J Health Econ. 2021;22(9):1467–75.

66. Wu CY, Hung SJ, Lin KC, Chen KH, Chen P, Tsay PK. Responsiveness, minimal clinically important difference, and validity of the MoCA in stroke rehabilitation. Occup Ther Int. 2019;2019(2517658):662–73.

67. Dromerick AW, Edwards DF, Diringer MN. Sensitivity to changes in disability after stroke: a comparison of. J Rehabil Res Dev. 2003;40(1–4):1–8.

68. Chen P, Lin KC, Liing RJ, Wu CY, Chen CL, Chang KC. Validity, responsiveness, and minimal clinically important difference of EQ-5D-5L in stroke patients undergoing rehabilitation. Qual Life Res. 2016;25:1585–96.

69. Lemay KR, Tulloch HE, Pipe AL, Reed JL. Establishing the minimal clinically important difference for the hospital anxiety and depression scale in patients with cardiovascular disease. J Cardiopulm Rehabil Prev. 2019;39(6):E6-11.

70. Vinkers DJ, Gussekloo J, Stek ML, Westendorp RG, Van Der Mast RC. The 15-item Geriatric Depression Scale (GDS-15) detects changes in depressive symptoms after a major negative life event. The Leiden 85-plus Study. Int J Geriatric Psychiatry. 2004;19(1):80–4.

71. Rooney S, McFadyen A, Wood L, Moffat F, Paul L. Minimally important difference of the fatigue severity scale and modified fatigue impact scale in people with multiple sclerosis. Multiple Sclerosis Relat Disord. 2019;1(35):158–63.

72. Espie CA, Farias Machado P, Carl JR, Kyle SD, Cape J, Siriwardena AN, Luik AI. The Sleep Condition Indicator: reference values derived from a sample of 200 000 adults. J Sleep Res. 2018;27(3):e12643.

73. Douiri A, Rudd AG, Wolfe CD. Prevalence of poststroke cognitive impairment: South London stroke register 1995–2010. Stroke. 2013;44(1):138–45.

74. Mahon S, Parmar P, Barker-Collo S, Krishnamurthi R, Jones K, Theadom A, Feigin V. Determinants, prevalence, and trajectory of long-term post-stroke cognitive impairment: results from a 4-year follow-up of the ARCOS-IV study. Neuroepidemiology. 2017;49(3–4):129–34.

75. Sensenbrenner B, Rouaud O, Graule-Petot A, Guillemin S, Piver A, Giroud M, Béjot Y, Jacquin-Piques A. High prevalence of social cognition disorders and mild cognitive impairment long term after stroke. Alzheimer Dis Assoc Disord. 2020;34(1):72–8.

76. Rohde D, Gaynor E, Large M, Mellon L, Bennett K, Williams DJ, Brewer L, Hall P, Callaly E, Dolan E, Hickey A. Cognitive impairment and medication adherence post-stroke: a five-year follow-up of the ASPIRE-S cohort. PLoS One. 2019;14(10):e0223997.

77. Delavaran H, Jönsson AC, Lövkvist H, Iwarsson S, Elmståhl S, Norrving B, Lindgren A. Cognitive function in stroke survivors: a 10-year follow-up study. Acta Neurol Scand. 2017;136(3):187–94.

78. Barker-Collo S, Starkey N, Lawes CM, Feigin V, Senior H, Parag V. Neuropsychological profiles of 5-year ischemic stroke survivors by Oxfordshire stroke classification and hemisphere of lesion. Stroke. 2012;43(1):50–5.

79. Schaapsmeerders P, Maaijwee NA, van Dijk EJ, Rutten-Jacobs LC, Arntz RM, Schoonderwaldt HC, Dorresteijn LD, Kessels RP, de Leeuw FE. Long-term cognitive impairment after first-ever ischemic stroke in young adults. Stroke. 2013;44(6):1621–8.

80. Turunen KE, Laari SP, Kauranen TV, Uimonen J, Mustanoja S, Tatlisumak T, Poutiainen E. Domain-specific cognitive recovery after first-ever stroke: a 2-year follow-up. J Int Neuropsychol Soc. 2018;24(2):117–27.

81. Nys GM, Van Zandvoort MJ, De Kort PL, Jansen BP, Van der Worp HB, Kappelle LJ, De Haan EH. Domain-specific cognitive recovery after first-ever stroke: a follow-up study of 111 cases. J Int Neuropsychol Soc. 2005;11(7):795–806.

82. Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke. 2013;44(4):1105–10.

83. Lapin BR, Thompson NR, Schuster A, Katzan IL. Magnitude and variability of stroke patient-proxy disagreement across multiple health domains. Arch Phys Med Rehabil. 2021;102(3):440–7.

84. Rand SE, Caiels J. Using proxies to assess quality of life: a review of the issues and challenges. Quality and Outcomes of person-centred care policy Research Unit (QORU), University of Kent.https://kar.kent.ac.uk/55009/.

85. Winward C, Sackley C, Metha Z, Rothwell PM. A population-based study of the prevalence of fatigue after transient ischemic attack and minor stroke. Stroke. 2009;40(3):757–61. https://doi.org/10.1161/STROKEAHA.108.527101.

86. Hinkle JL, Becker KJ, Kim JS, Choi-Kwon S, Saban KL, McNair N, Mead GE. Poststroke fatigue: emerging evidence and approaches to management: a scientific statement for healthcare professionals from the American Heart Association. Stroke. 2017;48(7):e159–70.

87. Van Dalen JW, van Charante EP, Nederkoorn PJ, van Gool WA, Richard E. Poststroke apathy. Stroke. 2013;44(3):851–60. https://doi.org/10.1161/STROKEAHA.112.674614.

88. Sagen-Vik U, Finset A, Moum T, Vik TG, Dammen T. The longitudinal course of anxiety, depression and apathy through two years after stroke. J Psychosom Res. 2022;1(162):111016. https://doi.org/10.1016/j.jpsychores.2022.111016.

89. Baylor C, Yorkston KM, Jensen MP, Truitt AR, Molton IR. Scoping review of common secondary conditions after stroke and their associations with age and time post stroke. Top Stroke Rehabil. 2014;21(5):371–82.

90. Ilse IB, Feys H, De Wit L, Putman K, De Weerdt W. Stroke caregivers' strain: prevalence and determinants in the first six months after stroke. Disabil Rehabil. 2008;30(7):523–30.

91. Rigby H, Gubitz G, Phillips S. A systematic review of caregiver burden following stroke. Int J Stroke. 2009;4(4):285–92.

92. Denham AM, Wynne O, Baker AL, Spratt NJ, Loh M, Turner A, Magin P, Bonevski B. The long-term unmet needs of informal carers of stroke survivors at home: a systematic review of qualitative and quantitative studies. Disabil Rehabil. 2022;44(1):1–2.

93. Calamia M, Markon K, Tranel D. Scoring higher the second time around: meta-analyses of practice effects in neuropsychological assessment. Clin Neuropsychol. 2012;26(4):543–70.

Kusec *et al. BMC Neurology*   (2023) 23:426

Page 17 of 17

94. Hurford R, Charidimou A, Fox Z, Cipolotti L, Werring DJ. Domain-specific trends in cognitive impairment after acute ischaemic stroke. J Neurol. 2013;260:237–41. https://doi.org/10.1007/s00415-012-6625-0.

95. Lugtmeijer S, Lammers NA, de Haan EH, de Leeuw FE, Kessels RP. Post-stroke working memory dysfunction: a meta-analysis and systematic review. Neuropsychol Rev. 2021;31:202–19.

96. Shin MS, Park SY, Park SR, Seol SH, Kwon JS. Clinical and empirical applications of the Rey-Osterrieth complex figure test. Nat Protoc. 2006;1(2):892–9. https://doi.org/10.1038/nprot.2006.115.

97. Webb SS, Moore MJ, Yamshchikova A, Kozik V, Duta MD, Voiculescu I, Demeyere N. Validation of an automated scoring program for a digital complex figure copy task within healthy aging and stroke. Neuropsychology. 2021;35(8):847. https://doi.org/10.1037/neu0000748.

98. Markus HS, de Leeuw FE. Cerebral small vessel disease: Recent advances and future directions. Int J Stroke. 2023;18(1):4–14. https://doi.org/10.1177/17474930221144911.

99. Prins ND, Van Dijk EJ, Den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128(9):2034–41. https://doi.org/10.1093/brain/awh553.

100. Chechlacz M, Novick A, Rotshtein P, Bickerton WL, Humphreys GW, Demeyere N. The neural substrates of drawing: a voxel-based morphometry analysis of constructional, hierarchical, and spatial representation deficits. J Cogn Neurosci. 2014;26(12):2701–15. https://doi.org/10.1162/jocn_a_00664.

101. Chen H, Pan X, Lau JK, Bickerton WL, Pradeep B, Taheri M, Humphreys G, Rotshtein P. Lesion-symptom mapping of a complex figure copy task: A large-scale PCA study of the BCoS trial. NeuroImage. 2016;11:622–34. https://doi.org/10.1016/j.nicl.2016.04.007.

102. Lammers NA, Van Wanrooij LL, van Dalen JW, van Gool WA, Schmand B, Moll van Charante EP, de Haan EH, Van de Beek D, Nederkoorn PJ, Richard E. The course of post-stroke apathy in relation to cognitive functioning: a prospective longitudinal cohort study. Aging Neuropsychol Cogn. 2021:1–2.

103. Skoglund E, Westerlind E, Persson HC, Sunnerhagen KS. Self-perceived impact of stroke: a longitudinal comparison between one and five years post-stroke. J Rehabil Med. 2019;51(9):660–4. https://doi.org/10.2340/16501977-2595.

104. Ward NS, Brander F, Kelly K. Intensive upper limb neurorehabilitation in chronic stroke: outcomes from the Queen Square programme. J Neurol Neurosurg Psychiatry. 2019;90(5):498–506.

105. Carlew AR, Fatima H, Livingstone JR, Reese C, Lacritz L, Pendergrass C, Bailey KC, Presley C, Mokhtari B, Cullum CM. Cognitive assessment via telephone: a scoping review of instruments. Arch Clin Neuropsychol. 2020;35(8):1215–33. https://doi.org/10.1093/arclin/acaa096.

106. Caughlin S, Mehta S, Corriveau H, Eng JJ, Eskes G, Kairy D, Meltzer J, Sakakibara BM, Teasell R. Implementing telerehabilitation after stroke: lessons learned from Canadian trials. Telemedicine e-Health. 2020;26(6):710–9. https://doi.org/10.1089/tmj.2019.0097.

107. Webb SS, Carrick C, Kusec A, Demeyere N. Introducing the Tele-OCS: A validated remotely administered version of The Oxford Cognitive Screen. Health Open Res. 2023;5(8):8.

108. Chapman JE, Gardner B, Ponsford J, Cadilhac DA, Stolwyk RJ. Comparing performance across in-person and videoconference-based administrations of common neuropsychological measures in community-based survivors of stroke. J Int Neuropsychol Soc. 2021;27(7):697–710.

Publisher's Note